W. Thomas London, MD - Internal Medicine/Hepatology
Dr. W. Thomas London, MD reviews medical content for Healthwise, a nonprofit organization with a mission to help people make better health decisions. Dr. London is a senior member in the Division of Population Science and director of the Liver Cancer Prevention Center at the Fox Chase Cancer Center and is widely published in peer-reviewed publications.
Dr. London received the Distinguished Scientist Award in 1998 from the Hepatitis B Foundation in Doylestown, Pennsylvania, and the Distinguished Interdisciplinary Research Award in 1999 from the American Cancer Society, Southeast Region.
Dr. London is Vice President of the Board Directors of the Hepatitis B Foundation in Doylestown and is also a member of the foundation's Medical Advisory Board. He is a member of the Boards Institute for Virus and Hepatitis Research and the Pennsylvania BioTechnology Center, also located in Doylestown.
- MD: Cornell University Medical College, New York, NY, 1957
- Internship: Bellevue Hospital, 2nd Cornell Medical Division, New York, NY, 1957–1958
- Residency: Medicine, Bellevue Hospital, 2nd Medical Division and Memorial Center (Combined Program), 1958–1960
- Fellowship: Research Fellowship in Medicine (Endocrinology) Sloan-Kettering Institute, New York, NY, 1960–1962
- Senior Member, Division of Population Science, Fox Chase Cancer Center, Philadelphia, PA, 1990–present
- Adjunct Professor of Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, 1999–2006
- American Association for Cancer Research
- American Association for the Advancement of Science
- American Board of Internal Medicine
- American College of Physicians
- American Liver Foundation
- American Medical Association
- American Society for Virology
- American Society of Preventive Oncology
- Hepatitis B Foundation
- Philadelphia County Medical Society
- Evans AA, O'Connell AP, Mason WS, M'boup S, Shen FM, London WT (In press). Heterogeneity of the pre-C/C region of hepatitis B virus (HBV) in chronic carriers from China and West Africa. In J Margolis et al., eds., Viral Hepatitis and Liver Disease. London: International Medical Press.
- Gao LL, Chen G, Evans AA, Lin WY, O'Connell AP, Propert KJ, Williams S, Shen FM, London WT, Haimen City Cooperating Group (In press). Predicting hepatocellular carcinoma: A model developed from a 4-year prospective study of hepatitis B virus carriers. In H Margolis et al., eds., Viral Hepatitis and Liver Disease. London: International Medical Press.
- McGlynn KA, Edmondson MN, Michielli RA, London WT, Lin WY, Shen FM, Buetow KH (2002). A phylogenetic analysis of loss of heterozygosity in hepatocellular carcinoma. Hepatology, 36(6): 1341–1348.
- Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT (2002). Eight-year follow-up of the 90,000-person Haimen City Cohort: I . Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiology Biomarkers and Prevention, 11(4): 369–376.
- London WT (2002). Liver cancer: Etiology and prevention. In J Bertino et al., eds., Encyclopedia of Cancer, 2nd ed. San Diego: Academic Press.
- Balsara BR, Pei J, De Rienzo A, Simon D, Tosolini A, Lu YY, Shen FM, Fan X, Lin WY, Buetow KH, London WT, Testa JR (2001). Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes, Chromosomes, and Cancer, 30(3): 245–253.
- Steel LF, Mattu TS, Mehta A, Hebesteit H, Dwek R, Evans A, London WT, Block T (2001). A proteomic approach for the discovery of early detection markers of hepatocellular carcinoma. Disease Markers, 17(3): 179–189.